Inflammasome Therapeutics has filed a notice of an exempt offering of securities to raise $3,796,600.00 in New Equity Investment.
According to filings with the U.S. Securities and Exchange Commission, Inflammasome Therapeutics is raising $3,796,600.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Paul Ashton played a key role…